Enliven Therapeutics (ELVN) Research & Development (2019 - 2026)
Enliven Therapeutics (ELVN) posted Research & Development of $20.7 million for Q1 2026, down 2.63% sequentially from $21.2 million in Q4 2025, and down 16.9% YoY from $24.9 million in Q1 2025.
Enliven Therapeutics (ELVN) Research & Development (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Research & Development for 8 years, with the latest figure at $20.7 million in Q1 2026.
- Quarterly Research & Development fell 16.9% year-over-year to $20.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.6 million (down 4.73% YoY) and the FY2025 annual result came in at $85.9 million, up 6.29% from the prior year.
- Research & Development retreated to $20.7 million in Q1 2026 per ELVN's latest filing, from $21.2 million in the prior quarter.
- Over five years, Research & Development peaked at $24.9 million in Q1 2025 and troughed at $7.1 million in Q1 2022.
- A 5-year average of $16.6 million and a median of $18.8 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development decreased 24.7% in 2022, then jumped 150.43% in 2023.
- Over 5 years, Research & Development stood at $8.2 million in 2022, then surged by 118.43% to $17.9 million in 2023, then climbed by 15.74% to $20.7 million in 2024, then advanced by 2.51% to $21.2 million in 2025, then decreased by 2.63% to $20.7 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $20.7 million, $21.2 million, and $18.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | 29.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.00 Mn |
| Mar 31, 2026 | 20.69 Mn |
| Dec 31, 2025 | 21.25 Mn |
| Sep 30, 2025 | 18.23 Mn |
| Jun 30, 2025 | 21.49 Mn |
| Mar 31, 2025 | 24.90 Mn |
| Dec 31, 2024 | 20.72 Mn |
| Sep 30, 2024 | 21.26 Mn |
| Jun 30, 2024 | 18.83 Mn |
| Mar 31, 2024 | 19.97 Mn |
| Dec 31, 2023 | 17.91 Mn |
| Sep 30, 2023 | 19.61 Mn |
| Jun 30, 2023 | 15.18 Mn |
| Mar 31, 2023 | 11.88 Mn |
| Dec 31, 2022 | 8.20 Mn |
| Sep 30, 2022 | 7.83 Mn |
| Jun 30, 2022 | 7.94 Mn |
| Mar 31, 2022 | 7.06 Mn |
| Dec 31, 2021 | 10.86 Mn |
| Sep 30, 2021 | 10.40 Mn |